DE69832176D1 - Arzneimittel gegen diabetes-komplikationen - Google Patents

Arzneimittel gegen diabetes-komplikationen

Info

Publication number
DE69832176D1
DE69832176D1 DE69832176T DE69832176T DE69832176D1 DE 69832176 D1 DE69832176 D1 DE 69832176D1 DE 69832176 T DE69832176 T DE 69832176T DE 69832176 T DE69832176 T DE 69832176T DE 69832176 D1 DE69832176 D1 DE 69832176D1
Authority
DE
Germany
Prior art keywords
ameliorating
efficacious
diabetes
drugs
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832176T
Other languages
English (en)
Other versions
DE69832176T2 (de
Inventor
Hiroshi Koga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69832176D1 publication Critical patent/DE69832176D1/de
Publication of DE69832176T2 publication Critical patent/DE69832176T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69832176T 1997-08-08 1998-08-07 Arzneimittel gegen diabetes-komplikationen Expired - Lifetime DE69832176T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21465997 1997-08-08
JP21465997 1997-08-08
PCT/JP1998/003525 WO1999007411A1 (fr) 1997-08-08 1998-08-07 Remedes contre les complications du diabete

Publications (2)

Publication Number Publication Date
DE69832176D1 true DE69832176D1 (de) 2005-12-08
DE69832176T2 DE69832176T2 (de) 2006-08-03

Family

ID=16659441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832176T Expired - Lifetime DE69832176T2 (de) 1997-08-08 1998-08-07 Arzneimittel gegen diabetes-komplikationen

Country Status (7)

Country Link
US (1) US6218411B1 (de)
EP (1) EP1004316B1 (de)
AT (1) ATE308342T1 (de)
AU (1) AU8561298A (de)
DE (1) DE69832176T2 (de)
ES (1) ES2251095T3 (de)
WO (1) WO1999007411A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
TW200626163A (en) * 2004-09-22 2006-08-01 Kureha Corp Agent for treating or preventing diabetic neuropathy
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
ES2420960T3 (es) * 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN102256488A (zh) * 2008-10-19 2011-11-23 理查德·J·约翰逊 伴随代谢失衡慢性肾病的治疗组合物和治疗方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940000232B1 (ko) * 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
AU3693789A (en) * 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
TW224941B (de) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CA2061179A1 (en) * 1991-02-18 1992-08-19 Ryuji Tsuzuki Oxzazinobenzazole compounds
ZA93436B (en) * 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
JPH08175994A (ja) * 1994-10-27 1996-07-09 Takeda Chem Ind Ltd 脂質代謝改善剤
CA2159851A1 (en) * 1994-11-07 1996-05-08 Gary J. Grover Combination of a potassium channel activator and a biguanide non-sulfonylurea agent
AU7888798A (en) * 1996-12-26 1998-07-31 Kirin Beer Kabushiki Kaisha Drugs for ameliorating ophthalmic circulatory disturbance

Also Published As

Publication number Publication date
ES2251095T3 (es) 2006-04-16
EP1004316B1 (de) 2005-11-02
DE69832176T2 (de) 2006-08-03
EP1004316A4 (de) 2003-02-12
US6218411B1 (en) 2001-04-17
EP1004316A1 (de) 2000-05-31
AU8561298A (en) 1999-03-01
ATE308342T1 (de) 2005-11-15
WO1999007411A1 (fr) 1999-02-18

Similar Documents

Publication Publication Date Title
DE69832176D1 (de) Arzneimittel gegen diabetes-komplikationen
BR9509853A (pt) Formulação farmacêutica uso da mesma e processos para fabricar a mesma para tratar um paciente em necessidade de tratamento anti-trombótico para tratar tromboembolismo e para intensificar a absorção do composto terapeuticamente ativo
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
CY2439B1 (en) Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermotological composition.
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
AU3459689A (en) Treatment of skin disorders
PT971694E (pt) Preparacoes de medicamentos para o tratamento de disfuncao sexual
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
DK0770384T3 (da) Faste, vandfrie farmaceutiske sammensætninger til vaginal anvendelse
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
NO984572L (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
ATE233085T1 (de) Arzneimittel zur topischen anwendung
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
WO2003082283A3 (en) Pharmaceutical composition with combined active agents and methods for using the same
ATE147983T1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
James NTZ submitted to FDA for cryptosporidiosis. Food and Drug Administration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition